Compare KMPR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMPR | SRPT |
|---|---|---|
| Founded | 1990 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1995 | 2000 |
| Metric | KMPR | SRPT |
|---|---|---|
| Price | $34.15 | $16.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 24 |
| Target Price | ★ $37.33 | $21.77 |
| AVG Volume (30 Days) | 809.0K | ★ 2.2M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | ★ $4,789,700,000.00 | $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.78 |
| Revenue Growth | ★ 3.26 | N/A |
| 52 Week Low | $22.69 | $14.68 |
| 52 Week High | $41.74 | $24.68 |
| Indicator | KMPR | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 37.20 |
| Support Level | $28.62 | $15.19 |
| Resistance Level | $34.64 | $18.26 |
| Average True Range (ATR) | 1.52 | 0.92 |
| MACD | 0.02 | -0.25 |
| Stochastic Oscillator | 68.55 | 8.92 |
Kemper Corp is an insurance holding company that offers complementary insurance products through its subsidiaries, including personal and commercial automobile insurance to consumers in targeted markets and industries. Kemper also offers life and other insurance solutions based on the needs of its clients. The company offers its insurance products through a vast network of agents and brokers, mainly under the Kemper Auto and Kemper Life brands. It has two operating segments: Specialty Property & Casualty Insurance and Life Insurance. The majority of the company's revenue is generated from the Specialty Property & Casualty Insurance segment, whose principal products are specialty personal automobile and commercial automobile insurance. Geographically, it operates only in the United States.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.